The post U.S. Jobless Claims Signal Labor Market Rebound as Fed Set to Hold Rates at January FOMC appeared on BitcoinEthereumNews.com. The U.S. initial jobless The post U.S. Jobless Claims Signal Labor Market Rebound as Fed Set to Hold Rates at January FOMC appeared on BitcoinEthereumNews.com. The U.S. initial jobless

U.S. Jobless Claims Signal Labor Market Rebound as Fed Set to Hold Rates at January FOMC

The U.S. initial jobless claims have come in lower than expectations, signaling a rebound in the job market after last year’s weak figures. This comes amid expectations that the Fed will hold rates steady at the January FOMC meeting.

U.S. Initial Jobless Claims Come In Below Expectations

Department of Labor data show that the adjusted initial claims for the week ending December 10 were 198,000, a decrease of 9,000 from the previous week’s revised level. The data also came in below expectations of 215,000, signaling a rebound in the labor market, with holiday-season volatility well over. This figure also marks the lowest level since November.

As CoinGape reported, the jobless claims for the week ending January 3 came in below expectations, at 208,000. The Department of Labor revised this figure to 207,00, further supporting the case of a rebound in the labor market.

This development comes as the Fed is likely to hold rates steady at the January FOMC meeting after making three rate cuts last year as insurance against further weakness in the labor market. CME FedWatch data shows there is currently a 95% chance the Fed leaves rates unchanged. Meanwhile, there is only a 5% chance they lower rates by 25 basis points (bps).

Notably, the PPI inflation data, which dropped yesterday, also strengthened the case for the Fed to hold rates steady, just like the initial jobless claims. The inflation data came in at 3%, suggesting that inflation in the country may be trending higher. Some Fed officials have continued to raise concerns that inflation remains above their 2% target and could rise further due to the Trump tariffs.

Fed’s Goolsbee Comments On The Economy

In a CNBC interview, Chicago Fed President Austan Goolsbee said he is not surprised by the low jobless claims figures. He further remarked that the Fed’s most important task is to bring inflation back to the 2% target.

The Fed president also mentioned that interest rates can still go down a fair amount, but that they need firm evidence that inflation is trending downwards. Goolsbee also expects to see Fed rate cuts this year, but needs data to affirm the outlook.

Meanwhile, he also touched on the Powell probe, noting that infringing on central bank independence leads to high inflation. U.S. President Donald Trump has continued to pressure the Fed to make larger cuts, aiming to bring interest rates down to at least 1%.

Source: https://coingape.com/u-s-jobless-claims-signal-labor-market-rebound-as-fed-set-to-hold-rates-at-january-fomc/

Market Opportunity
Union Logo
Union Price(U)
$0,00283
$0,00283$0,00283
-%2,07
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26